Cardiovascular Disease, Heart Failure
Conditions
Keywords
HeartMate 3, LVAS, LVAD, Heart-assist Devices, Advanced, Ventricular Dysfunction, refractory left ventricular, Thoratec Corporation
Brief summary
The purpose of this study is to evaluate a less invasive implantation technique of the HeartMate 3 Left Ventricular Assist System (HM 3 LVAS) in 10 patients.
Detailed description
This study will evaluate the less invasive implantation technique of the HM 3 LVAS.
Interventions
PROCEDURELess Invasive Surgery (LIS)
Less invasive HM 3 LVAD surgical implant procedure
DEVICEHeartMate 3™
HM 3 LIS
Sponsors
Thoratec Corporation
Abbott Medical Devices
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient or legal representative has signed Informed Consent Form (ICF) 2. Age ≥ 18 years 3. BSA ≥ 1.2 m2 4. NYHA IIIB or IV, or ACC/AHA Stage D 5. LVEF ≤ 25% 6. CI ≤ 2.2 L/min/m2, while not on inotropes (if Patient is treated with inotropes at baseline, this does not apply) 7. Patients must also meet one of the following: * On optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and are failing to respond, OR * In NYHA class IIIB or IV heart failure for at least 14 days AND dependent on intraaortic balloon pump (IABP) for at least 7 days, OR * Inotrope dependent/unable to wean from inotropes OR * Listed for transplant 8. Females of child bearing age must agree to use adequate contraception-
Exclusion criteria
1. Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy 2. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the Investigator 3. Existence of ongoing mechanical circulatory support (MCS) other than IABP 4. Positive pregnancy test if of childbearing potential 5. Lactating mothers 6. Presence of mechanical aortic cardiac valve 7. History of any organ transplant 8. Platelet count \< 100,000 x 103/L (\< 100,000/ml) 9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management 10. History of confirmed, untreated AAA \> 5 cm in diameter 11. Presence of an active, uncontrolled infection 12. Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy that the Investigator will require based upon the patients' health status 13. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure: * An INR ≥ 2.5 not due to anticoagulation therapy * Total bilirubin \> 43 umol/L (2.5 mg/dl), shock liver, or biopsy proven liver cirrhosis * History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC \< 0.7, or FEV1 \<50% predicted * Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention * History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (\> 80%) carotid artery stenosis * Serum Creatinine ≥ 221umol/L (2.5 mg/dl) or the need for chronic renal replacement therapy * Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration 14. Aortic valve regurgitation \> grade 1 15. Pre albumin \< 150 mg/L, or Albumin \< 30g/L (3 g/dL) 16. Planned Bi-VAD support prior to enrollment 17. Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia 18. Planned concomitant intra-cardiac cardiac surgery 19. Thrombus formation in the atrium or left ventricle identified by echocardiogram 20. Previous sternotomy or left-sided thoracotomy 21. Participation in any other clinical investigation that is likely to confound study results or affect the study 22. Any condition other than HF that could limit survival to less than 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of survival participants | 30 days |
Countries
Czechia, Germany
Outcome results
None listed